Synthesis, biological evaluation and computational studies of pyrazole derivatives as Mycobacterium tuberculosis CYP121A1 inhibitors. Issue 11 (26th August 2022)
- Record Type:
- Journal Article
- Title:
- Synthesis, biological evaluation and computational studies of pyrazole derivatives as Mycobacterium tuberculosis CYP121A1 inhibitors. Issue 11 (26th August 2022)
- Main Title:
- Synthesis, biological evaluation and computational studies of pyrazole derivatives as Mycobacterium tuberculosis CYP121A1 inhibitors
- Authors:
- Alshabani, Lama A.
Kumar, Amit
Willcocks, Sam J.
Srithiran, Gayathri
Bhakta, Sanjib
Estrada, D. Fernando
Simons, Claire - Abstract:
- Abstract : Pyrazole derivatives were evaluated using UV-vis and protein-detected 1D 19 F-NMR (Mtb CYP121A1 binding affinity), antimycobacterial determination (MIC) and computational studies illustrating the potential anti-TB properties of the compounds. Abstract : A series of imidazole and triazole diarylpyrazole derivatives were prepared using an efficient 5-step synthetic scheme and evaluated for binding affinity with Mycobacterium tuberculosis (Mtb) CYP121A1 and antimycobacterial activity against Mtb H37Rv. Antimycobacterial susceptibility was measured using the spot-culture growth inhibition assay (SPOTi): the imidazoles displayed minimum inhibitory concentration (MIC90 ) in the range of 3.95–12.03 μg mL −1 (10.07–33.19 μM) with 11f the most active, while the triazoles displayed MIC90 in the range of 4.35–25.63 μg mL −1 (11.88–70.53 μM) with 12b the most active. Assessment of binding affinity using UV-vis spectroscopy showed that for the imidazole series, the propyloxy (11f ) and isopropyloxy (11h ) derivatives of the 4-chloroaryl pyrazoles displayed Mtb CYP121A1 type II binding affinity with K d 11.73 and 17.72 μM respectively compared with the natural substrate cYY ( K d 12.28 μM), while in the triazole series, only the methoxy substitution with the 4-chloroaryl pyrazole (12b ) showed good type II Mtb CYP121A1 binding affinity ( K d 5.13 μM). Protein-detected 1D 19 F-NMR spectroscopy as an orthogonal strategy was used to evaluate ligand binding independent ofAbstract : Pyrazole derivatives were evaluated using UV-vis and protein-detected 1D 19 F-NMR (Mtb CYP121A1 binding affinity), antimycobacterial determination (MIC) and computational studies illustrating the potential anti-TB properties of the compounds. Abstract : A series of imidazole and triazole diarylpyrazole derivatives were prepared using an efficient 5-step synthetic scheme and evaluated for binding affinity with Mycobacterium tuberculosis (Mtb) CYP121A1 and antimycobacterial activity against Mtb H37Rv. Antimycobacterial susceptibility was measured using the spot-culture growth inhibition assay (SPOTi): the imidazoles displayed minimum inhibitory concentration (MIC90 ) in the range of 3.95–12.03 μg mL −1 (10.07–33.19 μM) with 11f the most active, while the triazoles displayed MIC90 in the range of 4.35–25.63 μg mL −1 (11.88–70.53 μM) with 12b the most active. Assessment of binding affinity using UV-vis spectroscopy showed that for the imidazole series, the propyloxy (11f ) and isopropyloxy (11h ) derivatives of the 4-chloroaryl pyrazoles displayed Mtb CYP121A1 type II binding affinity with K d 11.73 and 17.72 μM respectively compared with the natural substrate cYY ( K d 12.28 μM), while in the triazole series, only the methoxy substitution with the 4-chloroaryl pyrazole (12b ) showed good type II Mtb CYP121A1 binding affinity ( K d 5.13 μM). Protein-detected 1D 19 F-NMR spectroscopy as an orthogonal strategy was used to evaluate ligand binding independent of perturbations at the haem. For imidazole and triazole compounds, perturbations were more intense than cYY indicating tighter binding and confirming that ligand coordination occurs in the substrate-binding pocket despite very modest changes in UV-vis absorbance, consistent with computational studies and the demonstrated potential anti-tuberculosis properties of these compounds. … (more)
- Is Part Of:
- RSC medicinal chemistry. Volume 13:Issue 11(2022)
- Journal:
- RSC medicinal chemistry
- Issue:
- Volume 13:Issue 11(2022)
- Issue Display:
- Volume 13, Issue 11 (2022)
- Year:
- 2022
- Volume:
- 13
- Issue:
- 11
- Issue Sort Value:
- 2022-0013-0011-0000
- Page Start:
- 1350
- Page End:
- 1360
- Publication Date:
- 2022-08-26
- Subjects:
- Pharmaceutical chemistry -- Periodicals
615.19005 - Journal URLs:
- http://www.rsc.org/ ↗
https://www.rsc.org/journals-books-databases/about-journals/rsc-medicinal-chemistry ↗ - DOI:
- 10.1039/d2md00155a ↗
- Languages:
- English
- ISSNs:
- 2632-8682
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 8036.751550
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24796.xml